Satoshi Narahara

6PUBLICATIONS
24CO-AUTHORS
Predictive and prognostic markersDisease surveillanceCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 27, 2026
Nivolumab Plus Ipilimumab for Unresectable Hepatocellular Carcinoma in Early Real-World Clinical Practice: A Multicenter Analysis of Efficacy and Safety.

|Jul 06, 2026
Statin Use Is Associated With Improved Survival But Not Progression-Free Outcomes in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab-Bevacizumab.

|May 06, 2026
Rifaximin Improves Cognitive Performance and Reduces Cirrhosis-Related Adverse Events in Covert Hepatic Encephalopathy: A Randomized Controlled Trial.

|Mar 18, 2026
Impact of Etiological Shifts and the Rising Burden of Non-B Non-C Hepatocellular Carcinoma on Surveillance and Prognosis: Insights From a 20-Year Retrospective Observational Study.

Yoko Yoshimaru, Katsuya Nagaoka, Hiroko Setoyama

|May 03, 2025
Neutrophil-to-lymphocyte ratio at the start of the second course of durvalumab plus tremelimumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.

Takanori Suzuki, Kentaro Matsuura, Satoshi Sobue

|Nov 27, 2021
Clusterin and Related Scoring Index as Potential Early Predictors of Response to Sorafenib in Hepatocellular Carcinoma.

Satoshi Narahara, Takehisa Watanabe, Katsuya Nagaoka

Pageof 1

Frequent Collaborators

6 joint publications

Yasuhito Tanaka

4 joint publications

Hiroki Inada

3 joint publications

Takehisa Watanabe

3 joint publications

Hiroko Setoyama